
🎃The October issue is live! ✅Computational cytopathology ✅PEGASUS trial ✅Stroke fuels glioma progression ✅Adipocyte methionine in cancer cachexia ✅and more nature.com/natcancer/volumes…

Nature Cancer is a journal dedicated to publishing the latest advances across all areas of cancer research.

🎃The October issue is live! ✅Computational cytopathology ✅PEGASUS trial ✅Stroke fuels glioma progression ✅Adipocyte methionine in cancer cachexia ✅and more nature.com/natcancer/volumes…

Out today! An AI model infers spatial proteomic patterns at the single-cell level from routine H&E slides to predict molecular biomarkers, prognosis and immunotherapy response nature.com/articles/s43018-0…

Reach out to our Editor Julieta Alfonso at "Defining and defeating metastasis: from plasticity to immune evasion to therapy resistance" Symposium in Heidelberg from 10th-13th Nov embl.org/about/info/course-a… via @embl

Online today! OSM and TGFβ1 establish distinct stromal niches that sustain hybrid and late EMT states in mouse skin tumors @CedricBlanpain nature.com/articles/s43018-0…

News & Views AI for detection of adverse events in the real world by @GuillaumeJaume & Jakob Nikolas Kather @jnkath 👉nature.com/articles/s43018-0…
Read about an AI agent assisting clinicians in assessing immune-related adverse events now in Nature Cancer! @dbittermanmd nature.com/articles/s43018-0…

🌟Online now @ednacukierman, Igor Astsaturov & co uncover that CAFs fuel pancreatic tumor growth and immune suppression by transferring membrane lipids to cancer cells through trogocytosis. nature.com/articles/s43018-0…

Read about an AI agent assisting clinicians in assessing immune-related adverse events now in Nature Cancer! @dbittermanmd nature.com/articles/s43018-0…

Now Online! A genome-wide screen in E. coli identifies genetic determinants of intratumoral bacterial fitness and targets for therapeutic application. @arpaialab nature.com/articles/s43018-0…

💫Now online! de Sauvage and colleagues discuss the latest advances in therapy-driven cancer plasticity processes 🔗nature.com/articles/s43018-0… Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: nature.com/collections/gfbbj… nature.com/articles/s43018-0…

Attending #ESMO26? Our Senior Editor, @Vin_Giacco, will be there and looks forward to connecting with the oncology community. Get in touch to discuss your latest research and publishing opportunities at Nature Cancer.
Looking forward to attending the #ESMO26 Annual Meeting in Madrid! I'll be there representing @NatureCancer and meeting the oncology community. Happy to discuss your latest research, publishing opportunities, or ideas for the journal, please reach out. See you in Madrid 🇪🇸

🧬New in Nature Cancer: The phase 2 PEGASUS trial explores a ctDNA-guided strategy to de-escalate or escalate adjuvant therapy in patients with high-risk stage II and stage III colon cancer, moving us closer to more personalised treatment decisions. nature.com/articles/s43018-0…

📢Read our Series on Next-generation cancer therapeutics featuring commissioned Reviews and a selection of articles published in Nature Cancer! nature.com/collections/hehde…

📢Our September Issue is out! Read about generative AI for digital pathology, cancer immunometabolism, GITR antibody optimization, l-glutamine combination therapy, and more 🔗nature.com/natcancer/volumes…

🚨New in Nature Cancer Dr Gong and colleagues report findings from the phase 1 study evaluating L-glutamine + gemcitabine/nab-paclitaxel in untreated advanced PDAC. ORR 44%, including 12.5% CR, with median OS of 22 months. #PancreaticCancer @jgong15 nature.com/articles/s43018-0…

Now Online! The neuropeptide galanin impairs antitumor immunity in glioblastoma by interacting with its receptor GALR3 on monocytic myeloid-derived suppressor cells, promoting their infiltration and ferroptosis resistance. nature.com/articles/s43018-0…

Our August issue is live!🏖️ Featuring copper dependency in AML, iron-mediated ferroptosis, GPNMB-directed CAR-T cell therapy, IDH1-mutant vaccine in phase 1 trial, and more 🔗nature.com/natcancer/volumes…